Monovalent CD47 Binding Proteins - Caedo Oncology, Apr 23, 2026
Summary
Caedo Oncology AS has published patent application US20260109764A1 for monovalent CD47 binding proteins and antibodies for therapeutic use. The application, filed October 9, 2023, claims binding proteins with one antigen binding domain targeting specific amino acid residues (Q19, N45, T120, R121, E122, G123) within CD47 as defined by SEQ ID NO:19. The inventors are Kjetil Hestdal, Rolf Dagfinn Pettersen, Nina Richartz, Sittana Matar, and Seham Skah. This publication makes the application available for public inspection and potential prior art challenges.
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
Caedo Oncology AS has filed patent application US20260109764A1 with the USPTO covering monovalent CD47 binding proteins and antibody compositions. The application specifies antigen binding domains targeting six defined amino acid residues within CD47, with applications in cancer therapeutics indicated by CPC classification A61P 35/00.
For pharmaceutical companies and biotechnology firms working on CD47/SIRPα axis therapeutics, this publication establishes prior art as of the October 2023 filing date. Competitors developing similar monovalent binding proteins or antibodies targeting the same CD47 epitope should review their own patent positions against these claims.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MONOVALENT CD47 BINDING PROTEINS
Application US20260109764A1 Kind: A1 Apr 23, 2026
Assignee
Caedo Oncology AS
Inventors
Kjetil Hestdal, Rolf Dagfinn Pettersen, Nina Richartz, Sittana Matar, Seham Skah
Abstract
The present invention relates to binding protein or antibody comprising one antigen binding domain that binds to CD47, said antigen binding domain comprising a heavy chain variable region that comprises three complementarity determining regions (CDRs), and a light chain variable region that comprises three CDRs, wherein said antigen binding domain binds to Q19, N45, T120, R121, E122 and G123 within CD47 as defined by SEQ ID NO:19, and wherein said binding protein or antibody binds monovalently to CD47. Binding protein and antibody-based compositions, therapeutic methods and kits are also provided.
CPC Classifications
C07K 16/2803 A61K 47/6849 A61P 35/00 A61K 2039/505 C07K 2317/35 C07K 2317/52 C07K 2317/565 C07K 2317/569 C07K 2317/73 C07K 2317/92
Filing Date
2023-10-09
Application No.
19118115
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.